Media Kit

For Media Inquiries, please contact:

Christine Lindenboom
VP, Investor Relations & Corporate Communications
media@alnylam.com

Fact Sheets

• Alnylam Corporate Overview (PDF)
• RNA Interference (RNAi) and the Future of Drug Development (U.S. Version) (PDF)
• Hereditary ATTR Amyloidosis (hATTR amyloidosis) Backgrounder (PDF)
• APOLLO Phase 3 Clinical Trial Overview (U.S. Version) (PDF)
• Acute Hepatic Porphyria (AHP) Backgrounder (PDF)
• ENVISION Phase 3 Clinical Trial Overview (PDF)
• Givosiran Backgrounder (PDF)
• ONPATTRO® (patisiran) Product Fact Sheet (U.S. Version) (PDF)
• Lumasiran ILLUMINATE-A and -B Phase 3 Clinical Trial Overview (PDF)
• Lumasiran Backgrounder (PDF)
• Primary Hyperoxaluria Type 1 Backgrounder (PDF)
• Alnylam Assist Fact Sheet (PDF)
• HELIOS Fact Sheet (PDF)
• Vutrisiran Fact Sheet (PDF)
• APOLLO Fact Sheet (PDF)

Photos

Executive Officers

• John Maraganore (Portrait | Casual | Candid — JPG – 300 dpi)
• Barry Greene (Portrait | Casual | Candid — JPG – 300 dpi)

Illustrations

• RNAi Process (JPG – 526KB)
• RNAi Natural Process (JPG – 109KB)
• RNAi Therapeutic Process (JPG – 90KB)

Logos

• Alnylam Pharmaceuticals (TIF – 300dpi| JPG – 72KB)